Navigation Links
Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
Date:11/16/2009

ments for end-stage (hormone and chemotherapy refractory) prostate cancer and the survival time is estimated to be between 8 and 12 months.

About Hollis-Eden Pharmaceuticals

Hollis-Eden Pharmaceuticals is a development-stage company with two product candidates in clinical trials: Apoptone® (HE3235), in the dose-escalation portion of a Phase I/II trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone® and Triolex® represent the lead candidates from Hollis-Eden's small molecule platform based on metabolites or synthetic analogs of endogenous steroid hormones. For more information on Hollis-Eden please visit www.holliseden.com.

This press release contains forward-looking statements within the meaning of the federal securities laws concerning, among other things, the Apoptone® mechanism of action; that PSA levels will remain stable or continue to decline; and expanding subject eligibility criteria to include earlier-stage, chemotherapy-naive patients in a controlled Phase II Apoptone® trial. Any statement included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Hollis-Eden's actual results to differ materially from historical results or those expressed or implied by such forward-looking statements. Such statements are subject to certain risks and uncertainties inherent in the Company's business, including, but not limited to: the ability to complete preclinical and clinical trials successfully and within specified timelines, if at all; the ability to obtain regulatory approval for TRIOLEX(®) (HE3286), APOPTONE(®)<
'/>"/>

SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
2. Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
3. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
4. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
5. Curemark Presents at Springboard Enterprises Life Sciences Forum
6. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
7. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
8. DIATHERIX Laboratories Presents at Homeland Security Conference
9. Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
10. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
11. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Leatherwood Plastics has ... material, to stay competitive in the semiconductor, clean ... materials ultimately impact product quality and productivity, according ... , Established in 1980 in Lewisville, TX, ... fabricators have left the business. Much of Leatherwood’s ...
(Date:9/18/2014)... 18, 2014  MEI Pharma, Inc. (Nasdaq: MEIP ... novel therapies for cancer, announced today that Daniel P. ... at BioCentury,s NewsMakers in the Biotech Industry conference ... from the Millennium Broadway Hotel & Conference Center in ... presentation can be accessed at www.meipharma.com . A replay ...
(Date:9/18/2014)... Oncothyreon Inc. (NASDAQ: ONTY ) today announced ... offerings of 10,000,000 shares of its Common Stock at ... for expected gross proceeds of $20 million and 10,000 ... a price to the public of $2,000.00 per share, ... of Series A Convertible Preferred Stock is non-voting and ...
(Date:9/18/2014)... 2014   Sigma-Aldrich Corporation (Nasdaq: ... into a new gene editing partnership with the ... Under the partnership, Sigma-Aldrich will provide the Vector ... and dedicated gene editing bioinformaticians. The ... at the U-M Medical School. One initiative already ...
Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... Tips for Better Blood ... Sugar Management, BRIDGEWATER, N.J., ... with diabetes, Emmy nominated actress and,Broadway star Aida Turturro is teaming up ... diabetes to reach,better levels of blood sugar control. Ms. Turturro,s personal story ...
... security guards, police officers and armed forces into Robocops, repelling ... in carbon nanotechnology however could give those in the line ... of damage. , A research paper published in ... Centre for Advanced Materials Technology at the University of Sydney ...
... Dragon Pharmaceutical Inc.,(TSX: DDD; OTCBB: DRUG; BBSE: ... 7ACA production has been successfully implemented on ... validates the Company,s research,and development efforts to ... immediate benefits to production operations by,increasing production ...
Cached Biology Technology:Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes 2Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes 3Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes 4Using nanotech to make Robocops 2Dragon Announces R&D Achievement in Biotech Manufacturing Process 2Dragon Announces R&D Achievement in Biotech Manufacturing Process 3
(Date:9/18/2014)... cycles of carbon and nitrogen comprise all spheres ... environmental systems have caused imbalances and perturbations that ... (GHGs). Increased GHGs result in climate changes which ... oceans and the atmosphere. Understanding these feedback mechanisms ... of environmental science during the past three decades. ...
(Date:9/18/2014)... up to 400 kilometres in search of a home, which ... Clownfish spend their entire adult lives under the protection of ... open ocean, says study co-author, Dr Hugo Harrison from the ... at James Cook University. , "In the past we haven,t ... rare glimpse into how far they can swim, crossing large ...
(Date:9/17/2014)... engineering professor and his doctoral student have designed a ... water collected from fog and dew., The device could ... deserts around the globe., Cheng Luo, professor in the ... candidate in the same College of Engineering department, published ... of ACS, (American Chemical Society) Applied Materials ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2Nemo's epic journey to find a new home 2Shorebird's beak inspires UT Arlington research on water collection 2
... The majority of rare diseases are hereditary. But despite ... exact cause remains unclear. The discovery of the underlying ... diagnosis and the development of innovative approaches to their ... Genetics and the Institute of Medical Genetics at the ...
... The incidence of psychotic disorders varies greatly ... course, and treatment response across individuals. High rates ... cannabis users, and traumatised individuals reflect the causal ... progress in the area of molecular genetics, has ...
... the environment specifically to creatures that live in water ... Carolina State University toxicologists. In a study published in ... NC State researchers show that water fleas take up nitrates ... fertilizers and convert those chemicals into nitric oxide. Nitric ...
Cached Biology News:All genes in 1 go 2Developmental gene-environment interactions: A model for psychosis 2Developmental gene-environment interactions: A model for psychosis 3Developmental gene-environment interactions: A model for psychosis 4Developmental gene-environment interactions: A model for psychosis 5Developmental gene-environment interactions: A model for psychosis 6Fertilizer chemicals linked to animal developmental woes 2
Collected from sexually mature, mixed sex, mixed breed dogs. Serum from specific breeds available by request....
... EPS 301 Power Supply, 1. ... maximum.Constant voltage or constant current modes.Single-unit ... precision and reproducibility.Suitable for submarine, mini ... as well as semidry and mini ...
Mouse Serpin F1/PEDF MAb (Clone 199315)...
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
Biology Products: